

Ontario Public Drug Programs

Drug Submission Status
Updated: May 23, 2014

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Hospira Healthcare Corporation	Zoledronic Acid for Injection	Zometa Concentrate	zoledronic acid monohydrate	4mg/5mL	IV solution	02421550
Marcan Pharmaceuticals Inc.	Mar-Zolmitriptan	Zomig	zolmitriptan	2.5mg	FC tablet	02399458
Mint Pharmaceuticals Inc.	Mint-Ramipril	Altace	ramipril	15mg	capsule	02421348
Mint Pharmaceuticals Inc.	Mint-Zolmitriptan ODT	Zomig Rapimelt	zolmitriptan	2.5mg	orally disintegrating tablet	02419513
Sandoz Canada Inc.	Sandoz Olopatadine 0.2%	Pataday	olopatadine hydrochloride	0.2% w/v	ophthalmic solution	02420171